Boston Scientific, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Josh Jennings from TD Cowen maintained a Buy rating on the stock and has a $115.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Josh Jennings has given his Buy rating due to a combination of factors that indicate strong performance and growth potential for Boston Scientific. The company is expected to surpass its second-quarter estimates and slightly increase its 2025 organic sales growth guidance. Additionally, Boston Scientific is likely to raise its full-year earnings per share guidance, partly due to a more favorable tariff outlook.
Jennings highlights the sustained strong demand for key products like Farapulse and Watchman as significant growth drivers. The company is anticipated to maintain top-tier sales growth despite macroeconomic challenges. Furthermore, positive operating momentum and encouraging reports from industry peers bolster confidence in Boston Scientific’s ability to exceed both its own and market expectations.
According to TipRanks, Jennings is a 3-star analyst with an average return of 1.9% and a 50.10% success rate. Jennings covers the Healthcare sector, focusing on stocks such as TransMedics Group, Abbott Laboratories, and Boston Scientific.
In another report released on July 16, Bank of America Securities also maintained a Buy rating on the stock with a $115.00 price target.